Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

The purpose of the trial is to evaluate the antitumor activity and confirm the safety for the combination of Fibroblast Growth Factor Receptor (FGFR) inhibitor futibatinib and anti-programmed

  • 18 views
  • 10 Aug, 2022
  • 17 locations
A Study of TAS-120 in Patients With Metastatic Breast Cancer

The purpose of the trial is to evaluate a patient's response to a Fibroblast Growth Factor Receptor (FGFR) inhibitor, futibatinib (TAS-120), used either alone or in combination with the hormonal

fulvestrant
estrogen
endocrine therapy
her2-negative breast cancer
measurable disease
  • 76 views
  • 02 Jun, 2022
  • 31 locations
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-3248, an oral small molecule FGFR inhibitor, in adults with advanced

FGFR3
  • 5 views
  • 25 Jul, 2022
  • 4 locations
Study to Evaluate the Efficacy and Safety of TT-00420 in Cholangiocarcinoma

This study is an open-label, multicenter study to evaluate the efficacy and safety of TT-00420 tablet in adult patients with advanced cholangiocarcinoma.

measurable disease
neutrophil count
  • 0 views
  • 10 Aug, 2022
  • 5 locations
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

This phase II trial studies how well infigratinib works in treating solid tumors that have spread to other places in the body (advanced or metastatic) in patients with FGFR gene mutations such as FGFR1-3 gene fusions or other FGFR genetic alterations. Mutations are any changes in the genetic material (DNA) …

tumor cells
cancer
nervous
progressive disease
fgfr inhibitor
  • 0 views
  • 26 Mar, 2022
  • 1 location
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

The purpose of the study in Part 1 (dose escalation) is to determine the recommended Phase 2 dose(s) (RP2D[s]) and in Part 2 (dose expansion) is to determine the safety of Erdafitinib Intravesical Delivery System administered at the RP2D(s).

carcinoma
radical cystectomy
bladder tumor
  • 0 views
  • 25 Jul, 2022
  • 7 locations